Source:http://linkedlifedata.com/resource/pubmed/id/18719914
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2009-1-7
|
pubmed:abstractText |
CD8(+) T cells recognizing minor histocompatibility antigens (MiHA) on solid tumor cells may mediate effective graft-versus-tumor (GVT) reactivity after allogeneic stem cell transplantation (SCT). Previously, we identified LRH-1 as a hematopoietic-restricted MiHA encoded by the P2X5 gene. Here, we report that LRH-1 is aberrantly expressed on solid tumor cells. P2X5 mRNA expression is demonstrated in a significant portion of solid tumor cell lines, including renal cell carcinoma (RCC), melanoma, colorectal carcinoma, brain cancer and breast cancer. Importantly, P2X5 gene expression was also detected in a subset of primary solid tumor specimens derived from RCC, brain cancer and breast cancer patients. Furthermore, P2X5 expressing solid tumor cells can be effectively targeted by LRH-1-specific cytotoxic T lymphocytes under inflammatory conditions. The expression of HLA-B7 and CD54 on tumor cells increases upon cytokine stimulation resulting in improved T cell activation as observed by higher levels of degranulation and enhanced tumor cell lysis. Overall, hematopoietic-restricted MiHA LRH-1 is aberrantly expressed on solid tumor cells and may be used as target in GVT-specific immunotherapy after SCT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Minor Histocompatibility Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/P2RX5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2X5,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1432-0851
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
429-39
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:18719914-CD8-Positive T-Lymphocytes,
pubmed-meshheading:18719914-DNA-Binding Proteins,
pubmed-meshheading:18719914-Genotype,
pubmed-meshheading:18719914-Hematopoietic System,
pubmed-meshheading:18719914-Humans,
pubmed-meshheading:18719914-Immunotherapy,
pubmed-meshheading:18719914-Intercellular Adhesion Molecule-1,
pubmed-meshheading:18719914-Microscopy, Fluorescence,
pubmed-meshheading:18719914-Minor Histocompatibility Antigens,
pubmed-meshheading:18719914-Neoplasms,
pubmed-meshheading:18719914-RNA, Messenger,
pubmed-meshheading:18719914-Receptors, Purinergic P2,
pubmed-meshheading:18719914-Receptors, Purinergic P2X5,
pubmed-meshheading:18719914-Stem Cell Transplantation,
pubmed-meshheading:18719914-T-Lymphocytes,
pubmed-meshheading:18719914-Transcription Factors,
pubmed-meshheading:18719914-Transplantation, Homologous
|
pubmed:year |
2009
|
pubmed:articleTitle |
Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis.
|
pubmed:affiliation |
Central Hematology Laboratory, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|